Long-term secondary prophylaxis with recombinant activated factor VII (rFVIIa) in haemophilia A with inhibitors: a case report.
Peter
P
Kubisz
Ivana
I
Plamenová
Ján
J
Stasko
Miroslava
M
Dobrotová
Pavol
P
Hollý
D000293:Adolescent; D000906:Antibodies / Q000097:blood*; D003029:Coagulants / Q000276:immunology / Q000627:therapeutic use*; D005169:Factor VIII / Q000276:immunology / Q000627:therapeutic use*; D015942:Factor VIIa / Q000627:therapeutic use*; D006395:Hemarthrosis / Q000097:blood / Q000517:prevention & control*; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use; D055502:Secondary Prevention; D013997:Time Factors; D016896:Treatment Outcome
D000906:Antibodies; D003029:Coagulants; D011994:Recombinant Proteins; D005169:Factor VIII; C103587:recombinant FVIIa; D015942:Factor VIIa